Technology Commercialization Group, “TCG” Expands Again

Durham, NC – Jan Turek and Kathy Meserve have joined TCG, LLC in Durham, an international business development strategy and implementation firm, in response to an increase in life science business in the U.S. and Europe. Mr. Turek was President & CEO of Biolex for ten years, and as that unique therapeutic protein company grew, raised $185 million and completed a dozen commercial agreements with both US and international companies. He previously had a successful career in general management, global marketing, product management and sales at Bayer Pharmaceuticals and Sandoz in the US, Germany and Canada including Senior VP/General Manager of Bayer’s Biological Division, a $1 billion business with recombinant and plasma proteins focused on coagulation, respirology and immunology. Ms. Meserve has been President of Sequoia Research conducting business development, market research, partnering and project management for life sciences firms. She also brings experience in project and portfolio management, technology scouting, and drug product development from her extensive work experience. Kathy held key positions at Calvert Research and Amphora Discovery after a ten year career in development at Glaxo Smith Kline and R&D positions at Genentech.Both are active in the life sciences venture/business development community with Jan a Board member of SE BIO and Kathy as a mentor in the Healthcare Businesswomen’s Association and member of the Licensing Execs Society, CED and Women in Bio.